RT Journal Article
SR Electronic
T1 The role of the gluteofemoral adipose tissue in cerebrovascular disease risk: evidence from a mendelian randomization and mediation analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.08.24311685
DO 10.1101/2024.08.08.24311685
A1 Myserlis, Evangelos Pavlos
A1 Georgakis, Marios K.
A1 Parodi, Livia
A1 Mayerhofer, Ernst
A1 Rosand, Jonathan
A1 Banerjee, Chirantan
A1 Anderson, Christopher D.
YR 2024
UL http://medrxiv.org/content/early/2024/08/09/2024.08.08.24311685.abstract
AB Objective To explore causal associations between BMI-independent body fat distribution profiles and cerebrovascular disease risk, and to investigate potential mediators underlying these associations.Methods Leveraging data from genome wide association studies of BMI-independent gluteofemoral (GFAT), abdominal subcutaneous (ASAT), and visceral (VAT) adipose tissue volumes in UK Biobank, we selected variants associated with each trait, and performed univariable and multivariable mendelian randomization (MR) analyses on ischemic stroke and subtypes (large artery (LAS), cardioembolic (CES), small vessel (SVS)). We used coronary artery disease (CAD), carotid intima media thickness (cIMT), and an MRI-confirmed lacunar stroke as positive controls. For significant associations, we explored the mediatory role of four possible mediator categories in mediation MR analyses.Results Higher genetically proxied, BMI-independent GFAT volume was associated with decreased risk of ischemic stroke (FDR-p=0.0084), LAS (FDR-p=0.019), SVS (FDR-p<0.001), CAD (FDR-p<0.001), MRI-confirmed lacunar stroke (FDR-p=0.0053), and lower mean cIMT (FDR-p=0.0023), but not CES (FDR-p=0.749). Associations were largely consistent in pleiotropy- and sample structure-robust analyses. No association was observed between genetically proxied ASAT or VAT volumes and ischemic stroke/subtypes risk. In multivariable MR analyses, GFAT showed the most consistent independent association with ischemic stroke, LAS, and SVS. Common vascular risk factors were the predominant mediators in the GFAT-cerebrovascular disease axis, while adipose-tissue-specific adiponectin and leptin mediated a proportion of ischemic stroke and CAD risk.Interpretation Genetically proxied, BMI-independent higher GFAT volume is associated with reduced cerebrovascular disease risk. Although this is largely mediated by common vascular risk factor modification, targeting adipose-tissue specific pathways may provide additional cardiovascular benefit.Competing Interest StatementL.P. is an employee of L 'Oreal as of October 2023. E.M. is an employee of Regeneron as of July 2023. J.R. receives payments for consulting and expert testimony from the National Football League and Elli Lilly, and has a leadership or fiduciary role with Columbia University, European Stroke Journal, and Lancet Neurology. C.D.A. has received sponsored research support from Bayer AG, Massachusetts General Hospital, and the American Heart Association, is a member of the Editorial Board for Neurology, and has consulted for ApoPharma Inc. The rest of the authors have nothing to disclose.Funding StatementE.P.M. has received research support from the American Academy of Neurology (AWARD NO A24-0242-001). M.K.G. has received research support from the German Research Foundation (DFG) with an Emmy Noether grant (GZ: GE 3461/2-1, ID 512461526), the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy, ID 390857198), the Fritz-Thyssen Foundation with a research grant (Ref. 10.22.2.024MN), and the Hertie Foundation with a research fellowship (Hertie Network of Excellence in Clinical Neuroscience, ID P1230035). J.R. is supported by NIH 1U24NS127780, R01NS093870, 1U01NS102289, and AHA 23BFHSCP1176239, 812095, 814722. C.D.A. is supported by NIH R01NS103924, U01NS069673, AHA 18SFRN34250007, AHA-Bugher 21SFRN812095, and the MGH McCance Center for Brain Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that can be found at: common metabolic diseases (https://hugeamp.org)/cardiovascular disease (https://cvd.hugeamp.org)/cerebrovascular disease (https://cd.hugeamp.org)/type 2 diabetes (https://t2d.hugeamp.org) knowledge portal, GWAS catalog (https://www.ebi.ac.uk/gwas/), NIHLBI GRASP (Genome-Wide Repository of Associations Between SNPs and Phenotypes) catalog (https://grasp.nhlbi.nih.gov/FullResults.aspx), GLGC (Global Lipids Genetics Consortium) (https://csg.sph.umich.edu/willer/public/glgc-lipids2021/), MAGIC (Meta-Analyses of Glucose and Insulin-related Traits Consortium) website (http://magicinvestigators.org/downloads/), Karen Mohkle Lab website (https://mohlke.web.unc.edu/data/1719-2/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.